Briacell Therap (NASDAQ:BCTX) Short Interest Down 56.6% in June

Briacell Therap (NASDAQ:BCTX) was the target of a large decline in short interest in June. As of June 15th, there was short interest totaling 377,009 shares, a decline of 56.6% from the May 31st total of 867,761 shares. Approximately 4.4% of the shares of the stock are sold short. Based on an average daily volume of 250,931 shares, the days-to-cover ratio is presently 1.5 days.

Institutional Investors Weigh In On Briacell Therap

An institutional investor recently bought a new stake in Briacell Therap stock. Citadel Advisors LLC purchased a new position in shares of Briacell Therap (NASDAQ:BCTX) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 11,055 shares of the company’s stock, valued at approximately $122,000. Citadel Advisors LLC owned approximately 1.63% of Briacell Therap at the end of the most recent quarter. 15.42% of the stock is owned by hedge funds and other institutional investors.

Briacell Therap Price Performance

Shares of BCTX opened at $3.10 on Monday. The firm has a market capitalization of $26.98 million, a price-to-earnings ratio of -0.39 and a beta of 1.21. Briacell Therap has a 1-year low of $2.60 and a 1-year high of $31.10. The company has a 50-day moving average of $3.53 and a 200 day moving average of $4.75.

Briacell Therap (NASDAQ:BCTX) last issued its earnings results on Tuesday, June 9th. The company reported ($0.99) EPS for the quarter.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on BCTX shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Briacell Therap in a report on Monday, April 20th. Wall Street Zen raised Briacell Therap from a “strong sell” rating to a “sell” rating in a research note on Saturday, April 25th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Briacell Therap has an average rating of “Sell”.

Briacell Therap Company Profile

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers.